{
  "main_header": {
    "sid": 539063,
    "name": "Brooks Lab.",
    "stock_name": "Brooks Lab.",
    "full_name": "Brooks Laboratories Ltd",
    "name_url": "stocks-analysis/brooks-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "126.50",
    "chg": 1.65,
    "chgp": "1.32%",
    "dir": 1,
    "prev_price": "124.85",
    "mcapval": "372.63 Cr",
    "mcap": "Micro Cap",
    "scripcode": 533543,
    "symbol": "BROOKS",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE650L01011",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "23:59 PM",
    "bse_nse_vol": "27.56 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brooks-lab-539063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Brooks Laboratories Faces Short-Term Challenges Despite Long-Term Growth Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-reports-mixed-stock-performance-amid-significant-long-term-gains-1650044",
        "imagepath": "",
        "date": "2025-03-28 18:00:16",
        "description": "Brooks Laboratories, a microcap player in the Pharmaceuticals & Drugs industry, has experienced significant stock activity today. The company, with a market capitalization of Rs 290.00 crore, is currently facing a challenging period, reflected in its one-day performance, which shows a decline of 3.80%. This contrasts with the broader market, as represented by the Sensex, which has decreased by only 0.25% on the same day.\n\nOver the past year, Brooks Laboratories has outperformed the Sensex, achieving a return of 16.10% compared to the index's 5.11%. However, the stock has struggled in the short term, with a notable decline of 39.40% over the last three months and a year-to-date performance down by 41.75%. \n\nIn terms of valuation, Brooks Laboratories has a price-to-earnings (P/E) ratio of -13.76, significantly lower than the industry average of 26.76. This metric indicates potential concerns regarding profita..."
      },
      {
        "title": "Brooks Laboratories Reports Record Sales Amid Challenges in Debtor Management",
        "link": "https://www.marketsmojo.com/news/result-analysis/brooks-laboratories-reports-96-7-growth-in-net-sales-for-december-2024-1003710",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/BrooksLaborator_quaterlyResult_437113.png",
        "date": "2025-02-13 22:50:59",
        "description": "Brooks Laboratories reported its financial results for the quarter ending December 2024, showcasing a significant increase in net sales and operating profit, both reaching their highest levels in five quarters. However, the company faces challenges with a declining debtor turnover ratio, indicating issues in debt management."
      }
    ],
    "total": 21,
    "sid": "539063",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/brooks-laboratories-539063"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Please find enclosed intimation for closure of Trading window for the quarter and financial year ended 31st March 2025.The details of Board Meeting and opening of Trading Window shall be intimated in due course of time.",
      "source": "BSE"
    },
    {
      "caption": "Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December 2024 (Revised).",
      "datetime": "28-Feb-2025",
      "details": "Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.",
      "source": "BSE"
    },
    {
      "caption": "Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December 2024 (Revised).",
      "datetime": "28-Feb-2025",
      "details": "Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Brooks Laboratories Ltd has announced <strong>1:16</strong> rights issue, ex-date: 28 Jul 23",
          "dt": "2023-07-28",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Brooks Laboratories Faces Short-Term Challenges Despite Long-Term Growth Resilience

2025-03-28 18:00:16

Brooks Laboratories, a microcap player in the Pharmaceuticals & Drugs industry, has experienced significant stock activity today. The company, with a market capitalization of Rs 290.00 crore, is currently facing a challenging period, reflected in its one-day performance, which shows a decline of 3.80%. This contrasts with the broader market, as represented by the Sensex, which has decreased by only 0.25% on the same day. Over the past year, Brooks Laboratories has outperformed the Sensex, achieving a return of 16.10% compared to the index's 5.11%. However, the stock has struggled in the short term, with a notable decline of 39.40% over the last three months and a year-to-date performance down by 41.75%. In terms of valuation, Brooks Laboratories has a price-to-earnings (P/E) ratio of -13.76, significantly lower than the industry average of 26.76. This metric indicates potential concerns regarding profita...

Read More

Brooks Laboratories Reports Record Sales Amid Challenges in Debtor Management

2025-02-13 22:50:59

Brooks Laboratories reported its financial results for the quarter ending December 2024, showcasing a significant increase in net sales and operating profit, both reaching their highest levels in five quarters. However, the company faces challenges with a declining debtor turnover ratio, indicating issues in debt management.

Read More

View All News